Home
Graphite Bio, Inc.

Graphite Bio, Inc. Market Share Analysis for May 2026

LENZ Therapeutics is is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, focused on an eye drop to treat presbyopia and provide seamless vision for the vast majority of presbyopes.

Health > Biotechnology and Pharmaceuticals

Domaingraphitebio.com

Year Founded2017

Employees51 - 200

Annual Revenue$15M - $25M

Graphite Bio, Inc.

Graphite Bio, Inc. (including company regionals)

graphitebio.com

See more website traffic and engagement information

Graphite Bio, Inc. Revenue up to May 2026 is 15M - 25M

revenue generated by Graphite Bio, Inc. top domains

Graphite Bio, Inc. top domains revenue over 3 years

Revenue for Graphite Bio, Inc. top domains

graphitebio.com15M - 25M

See more with Sales Intelligence

Total visits to Graphite Bio, Inc.'s top domains

Understand Graphite Bio, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Graphite Bio, Inc.'s top domains

Analyze Graphite Bio, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Graphite Bio, Inc.'s top domains

See how Graphite Bio, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Graphite Bio, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Graphite Bio, Inc.

These are the website technologies, by industry, used by Graphite Bio, Inc. top domains

Widget (4)

Twemoji

Content Management System (2)

WordPress

Email Services (2)

Sendgrid

Mobile (2)

Meta Viewport

More Technologies

9

See all

News & Signals from Graphite Bio, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsLENZ Therapeutics, Inc. partnered with Graphite Bio, Inc. on Nov 15th '23.• Graphite Bio, the financially troubled gene-editing company, announced a merger with Lenz Therapeutics.

NewsGraphite Bio, Inc. merged with LENZ Therapeutics, Inc. on Nov 15th '23.Under the terms of the agreement, Graphite Bio will merge with LENZ Therapeutics in an all-stock transaction.

NewsAlethia Young left Graphite Bio, Inc. as Chief Financial Officer on Jun 23rd '23.Alethia is joining Bicycle from Graphite Bio, where she has been serving as the chief financial officer.